Supraorbital and infraorbital nerve blockade in migraine patients: results of 6-month clinical follow-up

Basit Öğe Kaydı
dc.authorscopusid24558887300
dc.authorscopusid14047809600
dc.contributor.authorAlp, Selen İlhan
dc.contributor.authorAlp, Recep
dc.date.accessioned2022-05-11T14:40:14Z
dc.date.available2022-05-11T14:40:14Z
dc.date.issued2013
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Nöroloji Ana Bilim Dalı
dc.description.abstractBACKGROUND: Nerve blockades are used for the treatment of acute migraine episodes in emergency room conditions and beneficial results are obtained from this clinical use. Although this is the case, there are limited numbers of studies investigating the long-term effects of such an approach. PATIENTS AND METHODS: In this investigation, we had 26 patients diagnosed as migraine based on the ICHD II criteria, these were injected with 1% lidocaine at supraorbital and infraorbital nerve localizations and clinical results were evaluated after 6 months of follow-up. All patients received 1.5 ml of 1% lidocaine bilaterally for supraorbital and infraorbital nerves with three day intervals for three times. Clinical evaluation was conducted by recording the number of migraine episodes per month together with migraine disability assessment scale (MIDAS) and visual analog scale (VAS) scores before and six months after the treatment. RESULTS: Mean age of the patients recruited in the study was 31.1 +/- 10.2 years. Disease duration was 8.1 +/- 5.4 years, the duration of the headache was 28.4 +/- 18.4 hours, mean number of episodes before treatment was 9.9 +/- 5.2, mean MIDAS was calculated as 3.2 +/- 0.8, and VAS as 9.0 +/- 1.0. Six months after the treatment, mean number of attacks was 2.0 +/- 3.0, MIDAS was 1.4 +/- 0.9 and VAS was 3.5 +/- 3.6. There was a statistically significant difference between the results obtained before and after the treatment. CONCLUSIONS: Injecting 1% of lidocaine to supraorbital and infraorbital nerve for three times prevents the acute migraine episodes effectively during the 6-months of follow-up without having any significant side effects
dc.identifier.endpage1781
dc.identifier.issn1128-3602
dc.identifier.issue13en_US
dc.identifier.pmid23852904
dc.identifier.scopus2-s2.0-84884195690
dc.identifier.scopusqualityQ2
dc.identifier.startpage1778
dc.identifier.urihttps://hdl.handle.net/20.500.11776/8912
dc.identifier.volume17
dc.identifier.wosWOS:000325203800014
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorAlp, Recep
dc.language.isoen
dc.publisherVerduci Publisher
dc.relation.ispartofEuropean Review For Medical and Pharmacological Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectMigraine
dc.subjectSupraorbital nerve blockade
dc.subjectInfraorbital nerve blockade
dc.subjectLidocaine
dc.subjectLocal anaesthetic blockade
dc.subjectGreater Occipital Nerve
dc.subjectPeripheral Mechanisms
dc.subjectHeadache
dc.subjectCost
dc.subjectCat
dc.titleSupraorbital and infraorbital nerve blockade in migraine patients: results of 6-month clinical follow-up
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu